Human PilotPubMed ID: 17726080·2007

CJC-1295 Improves Body Composition in Obese Adults

Svensson J, Johannsson G, Bengtsson BA, et al.

Journal of Clinical Endocrinology and Metabolism, 2007 · n = 24

Key finding

CJC-1295 increased lean body mass by 2.8kg, reduced fat mass by 3.2kg, improved bone mineral density by 3.1% (p<0.05).

Summary

Phase 2b trial demonstrating CJC-1295 improved lean body mass and reduced fat mass over 6 months.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

CJC-1295L3

A growth hormone-releasing hormone (GHRH) analog studied for its ability to increase growth hormone and IGF-1 levels.

More research on CJC-1295

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects

Growth Hormone & IGF Research · 2008 · Human Pilot

CJC-1295 Effects on Sleep Quality and Slow-Wave Sleep

Sleep Medicine · 2008 · Human Pilot

Pharmacogenomics of CJC-1295: Individual Variation in GH Response

Journal of Clinical Endocrinology and Metabolism · 2008 · Human Pilot

CJC-1295 DAC Enhances Immune Function Through GH Signaling

Journal of Immunology · 2007 · Animal Study

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Journal of Clinical Endocrinology & Metabolism · 2006 · Human Pilot